[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
Russia OKs Deal With Iran on Nuclear Fuel
Index:
Russia OKs Deal With Iran on Nuclear Fuel
International Isotopes Inc. Launches Lutetium-177
Westinghouse Announces Major Nuclear Fuel Agreement
==================================
Russia OKs Deal With Iran on Nuclear Fuel
MOSCOW (AP) - The Russian Cabinet has approved a draft agreement
requiring Iran to return to Russia all spent nuclear fuel from a
reactor it is helping build in Iran, the Interfax news agency
reported Friday.
Russia, which faces criticism from the United States over its nuclear
cooperation with Iran, has said it will not ship any fuel for the
reactor in the Persian Gulf city of Bushehr until an agreement
stipulating that Russia must return spent fuel is in place.
Russia has been negotiating with Iran, with the goal of signing the
agreement - making it enforceable.
U.S. officials have said the agreement - aimed at ensuring that Iran
would not be able to get plutonium, which can be derived from
reprocessing spent fuel from reactors - would reduce Washington's
concerns about Tehran's nuclear ambitions.
Russian officials have been saying for months that they are close to
signing the agreement. Iran's ambassador to Russia said in early June
that Iran was ready to sign the agreement but that Russia needed to
sort out internal obstacles linked to its environmental protection
legislation.
U.S. officials have worried for years that Russia's $800 deal to
build the reactor could help Iran develop nuclear weapons. Russian
officials have said the fears are unfounded, but have showed signs
recently that they may be becoming more cooperative with the United
States on the issue.
Russia has urged Iran to sign a document allowing closer inspections
by the International Atomic Energy Agency in order to ease concerns
that may be seeking to develop nuclear weapons, it has not linked
Iran's signing of the document to completion of the Bushehr plant.
------------------
International Isotopes Inc. Launches Lutetium-177
- Lutetium-177 to Be Used in the Clinical Trials for the Treatment of
Colon, Bone & Lung Cancer, and Non-Hodgkin's Lymphoma -
IDAHO FALLS, Idaho, Aug. 25 /PRNewswire-FirstCall/ -- International
Isotopes Inc. (OTC Pink Sheets: INIS), a manufacturer of nuclear
medicine calibration and reference standards and radioisotopes for
medical devices and clinical research, announces plans for the launch
of a new product -- Lutetium-177. The launch of the Lutetium-177
product is also being announced at the European Association of
Nuclear Medicine Congress taking place in Amsterdam, The Netherlands,
this week.
Lutetium-177 is currently being investigated in more than 30
different clinical applications including treatment of colon cancer,
metastic bone cancer, Non-Hodgkin's Lymphoma, and lung cancer. It is
estimated there are over 500,000 new cases of these cancers occurring
each year in the U. S. and nearly 2 million cases worldwide.
Clinical research with Lutetium-177 has been ongoing for several
years and the isotope has demonstrated certain chemical and
radiological properties which make it potentially very well suited as
a cancer therapy product.
International Isotopes Inc. is obtaining its Lutetium-177 through an
agreement put in place with the University of Missouri Research
Reactor (MURR).
The Company's Chief Executive Officer, Steve T. Laflin stated, "MURR
has been a leading developer of radioisotopes suitable for patient
trials and has also been a very reliable production source for these
isotopes. International Isotopes is pleased to have this agreement
in place with MURR as International Isotopes can take the product to
the next level and offer it on a global basis."
Laflin added, "The Company is very familiar with MURR and already has
a successful indirect relationship in place with them through another
of the Company's business lines. The Lutetium purchase agreement
provides us with an opportunity to further solidify our positive
relationship."
Representatives from the University of Missouri-Columbia stated, "We
continue to be excited about the cancer treating possibilities of
Lutetium-177 and believe its broader availability will encourage more
research and development of life saving cancer therapies."
In preparation for the commercialization of the Lutetium-177 product,
the Company has completed a facility expansion including hot cell and
laboratory equipment installations and has increased customer service
and marketing support.
----------------------
Westinghouse Announces Major Nuclear Fuel Agreement
PITTSBURGH, Aug. 25 /PRNewswire/ -- Westinghouse Electric Company
today announced that Exelon Generation has selected Westinghouse to
supply 16 reloads of commercial nuclear fuel for the Dresden 2 and 3
and Quad Cities 1 and 2 nuclear power plants.
Under terms of the contract, Westinghouse will supply its SVEA
OPTIMA2 boiling water reactor (BWR) fuel beginning with Quad Cities 2
in 2006. The Quad Cities plants are in Cordova, Ill., and the Dresden
plants are in Morris, Ill.
The fuel, to be manufactured at the Westinghouse fuel fabrication
facility in Columbia, S.C., is based on the fuel design currently
provided by the Westinghouse fuel facility in Vasteras, Sweden, to
customers primarily in Europe.
To date, Westinghouse has manufactured and delivered nearly 11,000 of
these fuel assemblies to reactors in Sweden, Finland, Germany,
Switzerland, Spain and the United States.
Westinghouse President and CEO Steve Tritch said the BWR agreement
with Exelon is the most recent example of the two companies working
together in a mutually beneficial manner. "Exelon is among our most
long-term and valued customers, and we are pleased to have the
opportunity to now provide BWR fuel to the Quad Cities and Dresden
plants," he said. "We have a long history together as we first began
providing PWR (pressurized water reactor) fuel to Exelon's Byron and
Braidwood plants in the 1980s."
Westinghouse Electric Company, wholly owned by BNFL plc of the United
Kingdom, is the world's pioneering nuclear power company and is a
leading supplier of nuclear plant products and technologies to
utilities throughout the world. Today, Westinghouse technology is the
basis for approximately one- half of the world's operating nuclear
plants.
-------------------------------------------------
Sandy Perle
Director, Technical
ICN Worldwide Dosimetry Service
ICN Plaza, 3300 Hyland Avenue
Costa Mesa, CA 92626
Tel:(714) 545-0100 / (800) 548-5100 Extension 2306
Fax:(714) 668-3149
E-Mail: sandyfl@earthlink.net
E-Mail: sperle@icnpharm.com
Personal Website: http://sandy-travels.com/
ICN Worldwide Dosimetry Website: http://www.dosimetry.com/
************************************************************************
You are currently subscribed to the Radsafe mailing list. To unsubscribe,
send an e-mail to Majordomo@list.vanderbilt.edu Put the text "unsubscribe
radsafe" (no quote marks) in the body of the e-mail, with no subject line.
You can view the Radsafe archives at http://www.vanderbilt.edu/radsafe/